Literature DB >> 28378193

Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis.

Daisuke Goto1, Ya-Chen Tina Shih2, Pascal Lecomte3, Melvin Olson3, Chukwukadibia Udeze4, Yujin Park5, C Daniel Mullins4.   

Abstract

Achieving comprehensive patient centricity in cost-effectiveness analyses (CEAs) requires a statistical approach that accounts for patients' preferences and clinical and demographic characteristics. Increased availability and accessibility of patient-level health-related utility data from clinical trials or observational database provide enhanced opportunities to conduct more patient-centered CEA. Regression-based approaches that incorporate patient-level data hold great promise for enhancing CEAs to be more patient centered; this paper provides guidance regarding two CEA approaches that apply regression-based approaches utilizing patient-level health-related utility and costs data. The first approach utilizes patient-reported preferences to determine patient-specific utility. This approach evaluates how individuals' unique clinical and demographic factors affect their utility and cost levels over the course of treatment. The underlying motivation of this approach is to produce CEA estimates that reflect patient-level utilities and costs while adjusting for socio-demographic and clinical factors to aid patient-centered coverage and treatment decision-making. In the second approach, patient utilities are estimated based on the clinically defined health states through which a patient may transition throughout the course of treatment. While this approach is grounded on the widely used Markov transition model, we refine the model to facilitate an enhancement in conducting regression-based analysis to achieve transparent understanding of differences in utilities and costs across diverse patient populations. We discuss the unique statistical challenges of each approach and describe how these analytical strategies are related to non-regression-based models in health services research.

Entities:  

Mesh:

Year:  2017        PMID: 28378193     DOI: 10.1007/s40273-017-0505-5

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  36 in total

Review 1.  Testing the validity of cost-effectiveness models.

Authors:  C McCabe; S Dixon
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

2.  Statistical analysis of correlated data using generalized estimating equations: an orientation.

Authors:  James A Hanley; Abdissa Negassa; Michael D deB Edwardes; Janet E Forrester
Journal:  Am J Epidemiol       Date:  2003-02-15       Impact factor: 4.897

Review 3.  Health outcomes in economic evaluation: the QALY and utilities.

Authors:  Sarah J Whitehead; Shehzad Ali
Journal:  Br Med Bull       Date:  2010-10-29       Impact factor: 4.291

Review 4.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.

Authors:  Scott Ramsey; Richard Willke; Andrew Briggs; Ruth Brown; Martin Buxton; Anita Chawla; John Cook; Henry Glick; Bengt Liljas; Diana Petitti; Shelby Reed
Journal:  Value Health       Date:  2005 Sep-Oct       Impact factor: 5.725

5.  Has the time come for cost-effectiveness analysis in US health care?

Authors:  Stirling Bryan; Shoshanna Sofaer; Taryn Siegelberg; Marthe Gold
Journal:  Health Econ Policy Law       Date:  2009-02-09

6.  Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.

Authors:  Marc L Berger; Muhammad Mamdani; David Atkins; Michael L Johnson
Journal:  Value Health       Date:  2009-09-29       Impact factor: 5.725

7.  Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.

Authors:  Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

8.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.

Authors:  Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder
Journal:  Value Health       Date:  2013 Mar-Apr       Impact factor: 5.725

9.  Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?-An Overview.

Authors:  Louis P Garrison
Journal:  Value Health       Date:  2016-06-28       Impact factor: 5.725

10.  Whither trial-based economic evaluation for health care decision making?

Authors:  Mark J Sculpher; Karl Claxton; Mike Drummond; Chris McCabe
Journal:  Health Econ       Date:  2006-07       Impact factor: 3.046

View more
  1 in total

Review 1.  Use of Claims Data for Cost and Cost-Effectiveness Research.

Authors:  Ya-Chen Tina Shih; Lei Liu
Journal:  Semin Radiat Oncol       Date:  2019-10       Impact factor: 5.934

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.